To ascertain the prognostic relevance of redox signatures in the context of immunotherapy, we assessed the relationship between redox scores and the efficacy of PD-1/PD-L1 checkpoint inhibitors in two distinct patient cohorts: the Ravi lung cancer cohort, the Gide melanoma cohort. This evidence concerns the gene CD274 and lung cancer.